Axsome’s Migraine Drug Provides Relief in Phase III Trial

Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.

The drug is a novel, oral, rapidly-absorbed drug with several methods of action. A new molecular entity, it utilizes the company’s Molecular Solubility Enhanced Inclusion Complex (MoSEIC) technology, which allows rapid absorption of meloxicam while maintaining a longer half-life in the blood. T